The Role of Interleukin-17 in Heart and Vascular Diseases at Thi-Qar Governorate


  • Department of Biology, College of education of pure science, University of Thi-Qar, Thi-Qar, Iraq
  • Department of Biology, College of education of pure science, University of Thi-Qar, Thi-Qar, Iraq


Heart and Vascular diseases, IL-17, smoking.


The objective of this study is to assess Interleukin-17 in cardiovascular patients. This study was conducted in the heart center in Thi-Qar Governorate, during the period between1/12/2023 to 1/4/2024. The study was investigated to measure Interleukin-17 (IL-17) levels in the serum using Enzyme-Linked Immunosorbent Assay (ELISA). The study included 100 participants: 50 patients with heart and vascular diseases and 50 healthy subjects serving as controls. The statistical analysis showed a significant increase in serum the mean concentration of (IL-17) in patients (10.90±4.28) pg/ml compared to the healthy control group (8.108±3.72) pg/ml with a statistically significant difference (P=0.001). So, it is concluded that the high level of IL-17 in the serum has to do with cardiovascular diseases.


M. Fakhry and A. Al-Aseel S. Worthan, “Prevention of cardiovascular disease. King Fahd University Hospital in Al-Khobar”. University of Dammam. 2017.

M. Veldhoen, Interleukin 17 is a chief orchestrator of immunity. Nature Immunology. Vol.18, pp. 612–621. 2017.

X. Zhang and F. Pei M. Zhang C. Yan M. Huang T. Wang Y. Han, “Interleukin-17A gene variants and risk of coronary artery disease: A large angiography-based study”. Clinica Chimica Acta 412, pp. 327–331. 2011.

G. Allam and A. Abdel-Moneim A. Gaber, “The pleiotropic role of interleukin-17 in atherosclerosis”. Biomedicine &Pharmacotherapy journal. 106. Pp.1412–1418. 2018.

E. Attia and A. Salman, “The Role of CXCR3 in Cardiovascular Disease Patients in Thi-Qar Province, Iraq”. NeuroQuantology: pp.211-214. 2022.

A. Csiszar and Z. Ungvari, “Synergistic effects of vascular IL-17 and TNFa may promote coronary artery disease”. Medical Hypotheses. 63, pp. 696–698. 2004.

S. Zhou and J. Yuan M. Liao N. Xia T. Tang J. Li J. Jiao W. Dong S. Nie Z. Zhu W. Zhang B. Lv H. Xiao Q. Wang X. Tu Y. Liao G. Shi X. Cheng, “IL-17A promotes ventricular remodeling after myocardial infarction,” J Mol Med. 92: pp.1105–1116. 2014.

M. Mora-Ruíz and F. Blanco-Favela A. Rueda M. Legorreta-Haquet L. Chávez-Sánchez, “Role of interleukin-17 in acute myocardial infarction”. Molecular Immunology 107. Pp. 71–78. 2019.

H. Wada and M. Nakamura S. Inoue K. Kudo T. Hanawa Y. Iwakura F. Kobayashi H. Kamma S. Kamiya K. Ito P. Barnes H. Takizawa, “Dual interleukin‑17A/F deficiency protects against acute and chronic responses to cigarette smoke exposure in mice”. Scientific Reports 11:11508. 2021.

T. Simon and S. Taleb N. Danchin L. Laurans B. Rousseau S. Cattan J. Montely O. Dubourg A. Tedgui S. Kotti Z. Mallat, “Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction”. European Heart Journal .34, pp.570–577. 2013.